89415-54-3

Usage

Uses

Used in Pharmaceutical Research:
5-Bromo-2-N-methylpyridine-2,3-diamine is utilized as a key intermediate in the synthesis of various pharmaceutical drugs. Its presence in the molecular structure of these drugs can enhance their therapeutic properties and effectiveness in treating specific medical conditions.
Used in Organic Synthesis:
As a derivative of pyridine, 5-Bromo-2-N-methylpyridine-2,3-diamine serves as a crucial component in the synthesis of a wide range of organic compounds. Its ability to participate in various chemical reactions makes it a valuable asset in the development of new organic materials and compounds.
Used in Material Development:
5-Bromo-2-N-methylpyridine-2,3-diamine also finds applications in the development of new materials. Its unique chemical properties can be harnessed to create innovative materials with specific characteristics, such as improved stability or enhanced reactivity.
Used as a Reagent in Chemical Reactions:
Due to its versatility, 5-Bromo-2-N-methylpyridine-2,3-diamine is employed as a reagent in various chemical reactions. It can act as a catalyst or a reactant, facilitating the formation of desired products and improving the efficiency of the reaction process.

Upstream product

• 70232-59-6 5-bromo-N-methyl-3-nitropyridin-2-amine 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 6945-68-2 5-bromo-3-nitro-pyridin-2-ylamine 
• 15862-37-0 2,5-dibromo-3-nitro-pyridine 

Downstream Products

• 37805-78-0 6-bromo-3-methylimidazo<4,5-b>pyridine 
• 92260-32-7 6-bromo-2,3-dimethyl-3H-imidazo[4,5-b]pyridine 
• 1366131-89-6 N-[5-bromo-2-(methylamino)-3-pyridinyl]benzenesulfonamide 
• 1366131-90-9 C₁₈H₂₄BN₃O₄S 
• 1366129-98-7 N-{5-{2-amino-3-[4-(ethylsulfonyl)phenyl]-6-quinolinyl}-2-(methylamino)-3-pyridinyl}benzenesulfonyamide 
• 1383944-56-6 6-bromo-2-(2-ethyl-sulfanyl-phenyl)-3-methyl-3H-imidazo[4,5-b]pyridine 
• 1383944-75-9 2-(2-ethylsulfanylphenyl)-6-(3-fluorophenyl)-3-methyl-3H-imidazo[4,5-b]pyridine 
• 1383944-72-6 2-(2-ethylsulfanylphenyl)-6-(2-fluorophenyl)-3-methyl-3H-imidazo[4,5-b]pyridine 
• 1383944-70-4 2-(2-ethylsulfanylphenyl)-3-methyl-6-phenyl-3H-imidazo[4,5-b]pyridine 
• 1383944-69-1 2-(2-ethyl-sulfanyl-phenyl)-3-methyl-6-pentafluoroethyl-3H-imidazo[4,5-b]pyridine 
• 1383944-66-8 6-difluoromethyl-2-(2-ethyl-sulfanyl-phenyl)-3-methyl-3H-imidazo[4,5-b]pyridine 

Relevant academic research and scientific papers

Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders

Selective inhibitors of the GluN2B subunit of N-methyl-d-aspartate receptors in the ionotropic glutamate receptor superfamily have been targeted for the treatment of mood disorders. We sought to identify structurally novel, brain penetrant, GluN2B-selective inhibitors suitable for evaluation in a clinical setting in patients with major depressive disorder. We identified a new class of negative allosteric modulators of GluN2B that contain a 1,3-dihydro-imidazo[4,5-b]pyridin-2-one core. This series of compounds had poor solubility properties and poor permeability, which was addressed utilizing two approaches. First, a series of structural modifications was conducted which included replacing hydrogen bond donor groups. Second, enabling formulation development was undertaken in which a stable nanosuspension was identified for lead compound 12. Compound 12 was found to have robust target engagement in rat with an ED70 of 1.4 mg/kg. The nanosuspension enabled sufficient margins in preclinical toleration studies to nominate 12 for progression into advanced good laboratory practice studies.

Quinazolinone Compound and Application Thereof

The present invention relates to a series of quinazolinone compounds and applications thereof as PI3Kα inhibitors. In particular, the present invention relates to a compound shown in formula (I) and a tautomer or pharmaceutically acceptable salt thereof.

SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted 1 H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

NRF2 REGULATORS

The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.

AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

METABOTROPIC GLUTAMATE RECEPTOR MODULATORS

The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders

INHIBITORS OF HIV REPLICATION

Compounds of formula (I): wherein R1, R2, A1, A2, A3, A4, X and Y are as defined herein, are useful as inhibitors of HIV replication.

1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c] quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H- imidazo[4,5-c] quinofinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c] quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H- imidazo[4,5-c] quinolinone derivatives; and a process for the preparation of the novel 1H- imidazo[4,5-c] quinolinone derivatives.

PI3 KINASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating the activity of PI3 kinase and, accordingly, useful for treatment of PI3 kinase mediated diseases, including melanomas, carcinomas and other cancer-related conditions. The compounds have a general Formula I wherein each of A1, A2, A3, A4, X, R1 and R2 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of PI3 kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

Antithrombotic quinoxazolines

Quinoxazolines having antithrombotic activity. Exemplary of those disclosed are: 4-{[6-(N-carboxymethyl-quinolin-8-yl-sulphonylamino)-1-methyl-2-oxo-1,2-dihydroquinoxalin-3-yl]-methyl}-benzamidine, 4-{[6-(1-(N-cyclopentyl-carboxymethylcarbonylamino)-cyclo-propyl)-1-methyl-2-oxo-1,2-dihydroquinoxalin-3-yl]-methyl}-benzamidine, and 4-{[7-(N-carboxymethylaminocarbonyl-ethylamino)-4-methyl-quinolin-2-yl]-oxo}-benzamidine.